Halofuginone, a febrifugine derivative, has emerged as a potential treatment through inhibiting Nrf2 translation and suppressing its cytoplasmic accumulation, thereby overcoming drug resistance and sensitizing lung cancer cells to chemo- and radiotherapy 102. The gene discussed is NFE2L2; the disease is lung carcinoma.